Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in Non-Small Cell Lung Cancers in Iran

Nourmohammadi, Bahareh; Tafsiri, Elham; Rahimi, Amir Abbas; Nourmohammadi, Zahra; Kakhaki, Abolghasem Daneshvar; Cho, William; Karimipoor, Morteza

doi:10.31557/apjcp.2019.20.6.1633

Cited by 15 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results as 6 miRNA MMP hub of smoking were obtained in Figure 5A (See Table 1 on high expression ( Figure 5A). This simulation result is well supported by ZEB2 oncogenic character that the expression level of ZEB1 and ZEB2 was correlated with NSCLC [109,110] and miR-154-5p regulated epithelialmesenchymal transition (EMT) in NSCLC [111]. miR-25-5p targets miR-1199-5p transcripts, and then miR-1199-5p targets ZEB2 ( Figure 5A).…”

Section: Smoking Simulationsupporting

confidence: 56%

Cancer Simulation from Stage Minus One by Quantum microRNA Language: Lung, Colorectal and Pancreatic Cancers

Fujii¹

2019

Med One

View full text Add to dashboard Cite

Background: The second, third, and fourth cases of lethal cause upon cancer are lung cancer, colorectal cancer, and pancreatic cancer, respectively. This trend is not limited to some countries, but is a global problem. To further decrease cancer-related death, early prediction, diagnosis and prognosis of cancer by noninvasive liquid biopsy is an urgent issue for us. It is related with saving lives at a low medical cost and cutting-edged ideas of a neo-medical tool for risk hedge. One of the biomarkers is circulating microRNA (miRNA). miRNA can control gene expression of protein and it is a common factor of tumorigenesis and tumor suppression. Although it has recently been cleared that miRNA panel as a biomarker could be measured and evaluated as an indicator of human diseases, it is remained unclear whether the miRNA biomarker could be evaluated as biological and pathogenic processes, or pharmacologic responses to a therapeutic intervention or not. Methods: To elucidate the implication between miRNA biomarkers and pathogenic processes, time-dependent processes of tumorigenesis in pancreatic, colorectal and lung cancers were investigated through network analysis from minus one stage (or stage zero) of cancer to various cancer stages by algorithm of miRNA entangling target sorting (METS) in silico simulation using quantum miRNA language. Results: We found three different miRNA memory package (MMP) hubs for pathogenic processes among three cancer cases. Conclusions: These computer simulation data suggested that quantum miRNA language would be essential for clinical miRNA biomarker panel to understand its biological, pathological and pharmaceutical characters in cancer.

show abstract

Section: Smoking Simulationsupporting

confidence: 56%

Cancer Simulation from Stage Minus One by Quantum microRNA Language: Lung, Colorectal and Pancreatic Cancers

Fujii¹

2019

Med One

View full text Add to dashboard Cite

show abstract

“…[6][7][8] ZEB1 was regulated by a series of regulatory RNA, including circular RNA, long non-coding RNA and microRNA. [9][10][11] To a great extent, ZEB1 overexpression was positively related with severity of lung cancer. ZEB1 overexpression also indicated a poor prognosis.…”

Section: Introductionmentioning

confidence: 98%

<p>Down-Regulation of ZEB1 by miR-199a-3p Overexpression Restrains Tumor Stem-Like Properties and Mitochondrial Function of Non-Small Cell Lung Cancer</p>

Bai¹,

Jiao²

2020

OTT

View full text Add to dashboard Cite

Objective: ) targeting of 3ʹ-UTR of ZEB1 was characterized as an important way to inhibit invasion and metastases in nonsmall cell lung cancer (NSCLC), one of the most common cancers around the world. Here we aimed to investigate the tumor-suppressive role of miR-199a-3p targeted ZEB1. Materials and Methods: A549 cells were transfected with ZEB1 and/or miR-199a-3p. Then, tumor growth was investigated in xenograft mice. Stem-like property, proliferation and mitochondria injury were further validated in vitro. Results: Overexpression of miR-199a-3p with premiRNAs significantly reduced tumor growth inhibited CD44 and Ki67 and increased Caspase-3 in A549 xenograft mice. Sphere formation and protein expression of stem-like markers showed that miR-199a-3p inhibited stemness of A549 cell. miR-199a-3p reduced proliferation of A549 cells, as showed with EdU staining and reduced expression of Ki67. Transfection of miR-199a-3p also promoted apoptosis, as indicated with increased apoptotic cells with flow cytometry, and increased cleaved Caspase-3/Caspase3 and Bcl-2/Bax. Apoptosis was further validated to be induced with mitochondria dysfunction, which indicated with JC-1 labeled loss of mitochondrial membrane potential, reduced activity of SOD, and increased MDA and LDH. All these effects were inverted with overexpression of ZEB1. Conclusion: Altogether, the findings suggested that the up-regulation of miR-199a-3p significantly inhibited NSCLC growth in vivo, and reduced A549 cell proliferation and promoted mitochondrial-mediated apoptosis, through down-regulation of ZEB1. The findings supported ZEB1 down-expression with miR-199a-3p as a novel therapeutic target for NSCLC treatment.

show abstract

“…4 A,B). Since the lung cancers reported in the Nourmohammadi et al 50 were non-FA-associated NSCLC, the miRNA-200C was no significant change. In contrast, the NSCLC samples in the FANCD2 foci negative cohort were FA defective tumors in the current study.…”

Section: Discussionmentioning

confidence: 91%

“…A recent study showed expression levels of miR-200C was no significant change in human non-small cell lung cancers (NSCLCs) as it is compared to normal adjacent tissues by real-time PCR 50 . In current study, the average of fold change on miRNA-200C in the 16 FANCD2 foci negative non-small cell lung cancer was 2.7 indicating overexpression in the foci negative tumors compared to matched non-tumor lung tissue.…”

Section: Discussionmentioning

confidence: 99%

MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers

Duan

Tang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The Fanconi Anemia (FA) pathway is essential for human cells to maintain genomic integrity following DNA damage. This pathway is involved in repairing damaged DNA through homologous recombination. Cancers with a defective FA pathway are expected to be more sensitive to cross-link based therapy or PARP inhibitors. To evaluate downstream effectors of the FA pathway, we studied the expression of 734 different micro RNAs (miRNA) using NanoString nCounter miRNA array in two FA defective lung cancer cells and matched control cells, along with two lung tumors and matched non-tumor tissue samples that were deficient in the FA pathway. Selected miRNA expression was validated with real-time PCR analysis. Among 734 different miRNAs, a cluster of microRNAs were found to be up-regulated including an important cancer related micro RNA, miR-200C. MiRNA-200C has been reported as a negative regulator of epithelial-mesenchymal transition (EMT) and inhibits cell migration and invasion by promoting the upregulation of E-cadherin through targeting ZEB1 and ZEB2 transcription factors. miRNA-200C was increased in the FA defective lung cancers as compared to controls. AmpliSeq analysis showed significant reduction in ZEB1 and ZEB2 mRNA expression. Our findings indicate the miRNA-200C potentially play a very important role in FA pathway downstream regulation.

show abstract

Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in Non-Small Cell Lung Cancers in Iran

Cited by 15 publications

References 46 publications

Cancer Simulation from Stage Minus One by Quantum microRNA Language: Lung, Colorectal and Pancreatic Cancers

Cancer Simulation from Stage Minus One by Quantum microRNA Language: Lung, Colorectal and Pancreatic Cancers

<p>Down-Regulation of ZEB1 by miR-199a-3p Overexpression Restrains Tumor Stem-Like Properties and Mitochondrial Function of Non-Small Cell Lung Cancer</p>

MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers

Contact Info

Product

Resources

About